Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Entity

Roivant Sciences

Tracked across 6 events · 72 articles · First seen May 23, 2025 · Last active Sep 23, 2026

Sentiment
9
Attention
4
Events
6
Relationships
2
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 -20
Business
Impact: Roivant Sciences announced the expansion of its brepocitinib program and the failure of Immunovant's batoclimab Phase 3 studies, which could negatively impact its stock.
Apr 02, 2026 · 16 articles
2 35
Domestic
Forbes reported on Sept. 20 that Vivek Ramaswamy, the Republican nominee for governor of United States — Ohio, is now worth an estimated $2.3 billion, up from $1.8 billion a year earlier and about $1…
Impact: Roivant Sciences is the main source of Ramaswamy's wealth, with shares near $40 and a roughly $29 billion market value after pipeline progress and the Moderna settlement. The attention reinforces its profile among biotech investors.
Sep 20, 2026 · 6 articles
4 65
Tech
Impact: Roivant Sciences is the parent company of Priovant Therapeutics. The positive trial results for brepocitinib, a key asset in its portfolio, are likely to boost investor confidence and the company's valuation.
Aug 26, 2026 · 7 articles
2 -25
Tech
Immunovant announced topline results from Period 1 of its proof-of-concept trial evaluating IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE). The randomized, double-blind, placebo-controlled global study enrolled 57 adult patients who were randomized to IMVT-1402 or…
Impact: Roivant, as Immunovant's majority owner, announced the topline results and shares in the pipeline setback. Its exposure is indirect but its equity stake and pipeline narrative are affected.
Sep 23, 2026 · 7 articles
4 0
Domestic
Impact: Roivant Sciences, a subsidiary of Roivant Sciences, settled with Moderna for $2.2 billion over unauthorized use of its patents in COVID vaccines.
May 02, 2026 · 30 articles
4 0
Business
Impact: Dr. Lynn Seely previously served as president, CEO, and board member of Roivant Sciences Inc., where she commercialized innovative therapies.
Apr 20, 2026 · 6 articles
Organon & Co. seller ↔ Roivant Sciences Roivant Sciences divested its dermatology subsidiary, Dermavant Sciences, to Org
Organon & Co. buyer ↔ Roivant Sciences Organon & Co. acquired Dermavant Sciences, a dermatology subsidiary, from Roivan
ERGEN INTELLIGENCE
Track Roivant Sciences live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.